neurosearch a s neur was founded in 1989 and is listed on the stock exchange in copenhagen nasdaq copenhagen a s . from its inception the company has focused its research and development activities on bringing drug candidates to market primarily in the cns segment . however in 2012 the company had to acknowledge that it was no longer able to attract funding for continuing its r & d activities . in the autumn of 2012 it was decided to accept an offer to sell all rigths to huntexil for the treatment of patients with huntington s disease to teva pharmaceuticals . the comapany s two remaining employees and its board of directors are now exploring the possibilities of a controlled disposal of its remaining assets . for a more detailed discussion of the situation see the company s annual report 2014 . the remaining assets consist of equity investments in the companies nsgene a s and atonomics a s contingent milestones from agreements with teva pharmaceuticals and an agreement with saniona a s which may also potentially produce royalties . finally the company has a portfolio of drug candidates which have alle been stopped at various stages of therie clinical development . for a more detailed description of the assets we also refer to the annual report 2014 . annual general meeting click here to be redirected to annual general meeting 19 april 2016 . calendar financial calendar latest news latest shareprice downloads & subscription presentations annual reports subscription service contentabout neurosearchmanagementaffiliatescorporate documentscontact usinvestor relationsannual general meetingextraordinary general meetingnews releasespresentationsfinancial reportsshare informationevent calendarmailing listcontact usinvestorportal neurosearch a s strandvejen 60 2900 hellerup denmark tel. 45 44 60 80 00 fax 45 44 60 80 80 cvr no . dk 1254 6106